NanoRibo (Shanghai) Biotechnology Co., Ltd., No. 1188 Lianhang Road, Minhang District, Shanghai 200003, China.
Brief Bioinform. 2024 Sep 23;25(6). doi: 10.1093/bib/bbae468.
Messenger RNA (mRNA) vaccines represent a groundbreaking advancement in immunology and public health, particularly highlighted by their role in combating the COVID-19 pandemic. Optimizing mRNA-based antigen expression is a crucial focus in this emerging industry. We have developed a bioinformatics tool named AntigenBoost to address the challenge posed by destabilizing dipeptides that hinder ribosomal translation. AntigenBoost identifies these dipeptides within specific antigens and provides a range of potential amino acid substitution strategies using a two-dimensional scoring system. Through a combination of bioinformatics analysis and experimental validation, we significantly enhanced the in vitro expression of mRNA-derived Respiratory Syncytial Virus fusion glycoprotein and Influenza A Hemagglutinin antigen. Notably, a single amino acid substitution improved the immune response in mice, underscoring the effectiveness of AntigenBoost in mRNA vaccine design.
信使 RNA(mRNA)疫苗代表了免疫学和公共卫生领域的一项突破性进展,特别是在抗击 COVID-19 大流行方面发挥了重要作用。优化基于 mRNA 的抗原表达是这一新兴产业的一个关键焦点。我们开发了一种名为 AntigenBoost 的生物信息学工具,用于解决阻碍核糖体翻译的不稳定二肽带来的挑战。AntigenBoost 在特定抗原内识别这些二肽,并使用二维评分系统提供一系列潜在的氨基酸替代策略。通过生物信息学分析和实验验证的结合,我们显著提高了体外表达的 mRNA 衍生的呼吸道合胞病毒融合糖蛋白和甲型流感血凝素抗原的水平。值得注意的是,单个氨基酸取代提高了小鼠的免疫反应,这突显了 AntigenBoost 在 mRNA 疫苗设计中的有效性。